DAOIB for the Treatment of Mild Cognitive Impairment
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
NMDA neurotransmission plays an important role in learning and memory. NMDA
receptor-enhancing agent improved the cognitive function of patients with early-phase
Alzheimer's disease. This study is a randomized, double-blind, placebo-controlled drug trial.
All subjects will be allocated randomly to 2 groups: (1) DAOIB group; (2) placebo group. The
study period is 24 weeks. The investigators hypothesize that DAOIB may yield better efficacy
than placebo for cognitive function in patients with mild cognitive impairment.